A phase II study of induction chemoradiotherapy plus surgery in patients with stage III non-small cell lung cancer
- Conditions
- on small cell lung cancer
- Registration Number
- JPRN-UMIN000005801
- Lead Sponsor
- Toho University Omori Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Not provided
) Blood transfusion within 14 days of therapy before enrollment, and preparations are treated with hematopoietic factor, those patients treated with antithrombotic agents for thrombosis. 2) Severe renal dysfunction, or urine protein 2+ or more cases. 3) Patient with severe drug allergy (anaphylaxis) 4) Patients with active double cancer 5) Patients with infectious diseases as a clinical problem, and suspected. 6) Poorly controlled hypertension, or patients with diabetes. 7) Significant ECG abnormalities, patients with heart disease as a clinical problem. 8) Patients with a history mager of Thrombosis or thrombosis severe lung disease within one year of the merger or previous thrombosis, severe lung disease (interstitial pneumonitis, pulmonary fibrosis, severe emphysema, etc.) within one year. 9) Patients with non-healing traumatic fracture 10) Patients with a history of mental disability, central nervus system disorder, cerebrovascular disease 11) In addition, patients who are considered not to participate in the study by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method